Toyota Global Sales Fall as China Demand Slumps 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Amazon Secures 200 MW Wind Power Deals in Sweden 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
(4) - EconoTimes)
Add as a preferred source on Google
SOUTH SAN FRANCISCO, Calif., April 09, 2018 -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported the grant of inducement awards to its Senior Vice President and General Counsel, Mina Kim, effective as of April 9, 2018. Ms. Kim has nearly 20 years of corporate legal experience, most recently as the General Counsel of the publicly listed companies Sunrun Inc. and Fly Leasing Limited.
The compensation committee of Atara's board of directors granted Ms. Kim a stock option to purchase 70,000 shares of Atara’s common stock, and restricted stock units to acquire 42,500 shares of Atara’s common stock. The stock option and restricted stock units were granted as an inducement material to Ms. Kim entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option has a seven-year term and an exercise price of $36.00, equal to the per share closing price of Atara's common stock as reported by Nasdaq on April 9, 2018. The awards vest over four years, with 25% vesting on the first anniversary of the grant date and the remainder vesting over the following three years, assuming the employee is continuously employed by Atara as of such vesting dates.
Atara is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. (@Atarabio) is a leading T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. The Company's off-the-shelf, or allogeneic, T-cells are bioengineered from donors with healthy immune function and allow for rapid delivery from inventory to patients without a requirement for pretreatment. Atara's T-cell immunotherapies are designed to precisely recognize and eliminate cancerous or diseased cells without affecting normal, healthy cells.
INVESTOR & MEDIA CONTACTS:
Investors:
John Craighead, Atara Biotherapeutics
650-491-5806
[email protected]
Steve Klass, Burns McClellan
212-213-0006 x331
[email protected]
Media:
Justin Jackson, Burns McClellan
212-213-0006 x327
[email protected]
